SP
Sun Pharma Advanced Research Company Limited
SPARC.NS · NSE
₹188.00 -4.47% (-₹8.79)
1M -3.19%
Market Cap ₹63.9B
P/E Ratio 4.04x
Div. Yield -
ROE 318.71%
Bulios Fair Price
₹279.72
48.8% upside
Current Price
₹188
Undervalued Fair Value Overvalued
According to Bulios Fair Price, SPARC.NS is currently undervalued relative to its market price. How does it work?
Bulios Fair Price is an estimate of a stock's fair value from the Bulios valuation model. It is an input for your own analysis, not investment advice. How does it work?
Analysis
An AI report on the business, its finances, valuation, sentiment, news and risks - written in a few minutes.
Piotroski F-Score Moderate
4/9Valuation
84 /100
Cheap P/S 3.35x
P/E 4.04x
P/B 4.78x
Growth
100 /100
Growing Book val. growth 37.70%
Rev. growth 98.91%
FCF growth N/A
Profitability
70 /100
Strong Op. margin 84.17%
Gross margin 93.29%
FCF margin 7.28%
Quality
100 /100
Excellent ROE 318.71%
Asset turnover N/A
ROIC N/A
Debt
100 /100
Low Net debt/EBITDA 0.00x
Debt/Equity 0.00x
Int. coverage 44.21x
Stability
28 /100
Unstable EPS volatility 333.03%
Beta 0.65x
Profitable years 1
Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more
Ask StockBot about SPARC.NS
Online
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
CEO
Anilkumar Raghavan
Employees
279
Headquarters
Mumbai